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Both the Safe Drinking Water Act (SDWA)
Amendments (1996) and the Food Quality
Protection Act (FQPA 1996) direct U.S.
Environmental Protection Agency (EPA) to
conduct studies to identify and characterize
health risks for groups that may be at greater
risk than the general population. For non-
cancer health effects, the FQPA (but not the
SDWA) mandates the use of a default addi-
tional 10-fold safety factor (10×) for protection
of children from noncancer effects unless spe-
ciﬁc data are available to indicate that this extra
protection is not needed. For carcinogenic
risks, as part of its revision of cancer risk assess-
ment guidelines, the U.S. EPA has assembled
and analyzed animal cancer bioassay data for
exposures to mutagenic and putatively nonmu-
tagenic chemicals over different periods of life.
On the basis of this analysis, the U.S. EPA
proposed a 10-fold upward adjustment in the
cancer potency for exposures to mutagenic car-
cinogens from birth to 2 years of age and a
3-fold adjustment for exposures between 3 and
15 years of age (U.S. EPA 2003).
In a previous report (Hattis et al. 2004), we
offered an improved analysis of the available
cancer bioassay data, using likelihood methods
to avoid excluding cases where no tumors were
observed in either adult or other groups and
providing for quantitative estimation of con-
fidence limits for the data as a whole, and
selected subsets of the data. We expressed
dosage for animals of different weights on a
metabolically consistent basis (either concentra-
tion in air or food, or per unit body weight to
the three-quarters power). Finally, we used a
system of dummy variables to represent expo-
sures during fetal, preweaning, and weaning
to 60-day postnatal periods—yielding sepa-
rate estimates of relative sensitivity per day of
dosing in these intervals.
Brieﬂy, the central estimate results of that
analysis indicated a 5- to 60-fold increased
carcinogenic sensitivity in the birth to wean-
ing period per dose/(body weight3/4-day) for
mutagenic carcinogens, and a somewhat
smaller increase—centered about 5-fold—for
radiation carcinogenesis per Gray (100 rads).
Effects were greater in males than in females,
partly because of considerable differences in
the carcinogenic responsiveness of the liver
in males. There was a similar increased sen-
sitivity in the fetal period for direct-acting
nitrosoureas, but no such increased fetal sen-
sitivity was detected for carcinogens requiring
metabolic activation.
This present article is a follow-up to that
earlier work (Hattis et al. 2004) showing
how the previous results might be applied to
distributional risk analyses of specific muta-
genic carcinogens. Doing this requires analy-
ses of three particular sources of uncertainty:
a) uncertainty in the central estimates of the
life-stage–speciﬁc sensitivity factors estimated
earlier, b) uncertainty from chemical-to-
chemical differences in life-stage–speciﬁc sen-
sitivities for carcinogenesis, and c) uncertainty
in the mapping of rodent life stages to human
ages/exposure periods. The implications of
these three component uncertainties are
assessed in Monte Carlo simulations.
Methodology and results from assessing
each source of uncertainty separately are cov-
ered in the next three subsections. This is fol-
lowed by a discussion of methodology and
results from the Monte Carlo simulations of
the combined effects. To convey our methods
and results as transparently as possible, and
allow others to extend the analyses, the under-
lying distributional input data and the Excel
Monte Carlo simulation models for each sex
are available via our website (Hattis 2004).
The results provide guidance on a) implica-
tions for human risk assessment for full life-
time exposures relative to adult-only exposures,
with comparisons with the human relative
susceptibility assumptions in the U.S. EPA
(2003) proposal and b) implications for
research priorities to reduce uncertainties.
Uncertainties in 
Central Estimates of
Life-Stage–Speciﬁc Sensitivity
to Carcinogenesis for
Mutagenic Agents
Table 1 and Figures 1 and 2 show the results
of our prior analyses (Hattis et al. 2004) of the
overall central tendency differences between
exposures during various life stages and similar
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In an earlier report we developed a quantitative likelihood-based analysis of the differences in
sensitivity of rodents to mutagenic carcinogens across three life stages (fetal, birth to weaning, and
weaning to 60 days) relative to exposures in adult life. Here we draw implications for assessing
human risks for full lifetime exposures, taking into account three types of uncertainties in making
projections from the rodent data: uncertainty in the central estimates of the life-stage–speciﬁc sen-
sitivity factors estimated earlier, uncertainty from chemical-to-chemical differences in life-
stage–speciﬁc sensitivities for carcinogenesis, and uncertainty in the mapping of rodent life stages
to human ages/exposure periods. Among the uncertainties analyzed, the mapping of rodent life
stages to human ages/exposure periods is most important quantitatively (a range of several-fold in
estimates of the duration of the human equivalent of the highest sensitivity “birth to weaning”
period in rodents). The combined effects of these uncertainties are estimated with Monte Carlo
analyses. Overall, the estimated population arithmetic mean risk from lifetime exposures at a con-
stant milligrams per kilogram body weight level to a generic mutagenic carcinogen is about
2.8-fold larger than expected from adult-only exposure with 5–95% confidence limits of 1.5-
to 6-fold. The mean estimates for the 0- to 2-year and 2- to 15-year periods are about 35–55%
larger than the 10- and 3-fold sensitivity factor adjustments recently proposed by the U.S.
Environmental Protection Agency. The present results are based on data for only nine chemicals,
including ﬁve mutagens. Risk inferences will be altered as data become available for other chemi-
cals. Key words: carcinogenesis, fetal, mutagenic chemicals, risk assessment, susceptibility, uncer-
tainties. Environ Health Perspect 113:509–516 (2005). doi:10.1289/ehp.7564 available via
http://dx.doi.org/ [Online 10 January 2005]exposure (per unit body weight3/4 or per unit
concentration in external air or water or food)
per day during adulthood (> 60 days of age in
rodents). There are appreciable differences
between the estimated life-stage–speciﬁc incre-
ments in relative risk for the two sexes; there-
fore, all the analyses in this article are done
separately for males and females.
The origins of the sex difference are not
known; however, we note that there are con-
spicuous differences between male and female
rodents in the levels of cytochrome P450
(CYP) enzymes that are responsible for meta-
bolic activation of several small-molecular-
weight mutagenic carcinogens. For example,
Chanas et al. (2003) have recently observed a
greater than 5-fold difference in CYP2E1 lev-
els in male than in female adult mice, and
associated this with an enhanced male sensi-
tivity to the toxicity of acrylonitrile. Early-life
differences in expression of speciﬁc CYPs have
been associated with sex differences in the fre-
quency of growth hormone pulses observed in
the plasma of rodents (Pampori and Shapiro
1994; Pampori et al. 2001; Shapiro et al.
1995). Sex differences are also apparent in the
induction of some DNA repair enzymes
in vivo in rodent liver. For example, Chan
et al. (1992) observed over a 17-fold induc-
tion of O6-methyl-guanine methyl transferase
activity in the livers of female Sprague-
Dawley rats after a high-dose (15 Gy) gamma
radiation exposure; this is compared with a
much smaller 3.5-fold induction in the livers
of male rats. Similar sex-related differences
were not observed in other organs. We are
not aware of direct comparisons of the induc-
tion of such DNA repair functions between
infant/juvenile and adult animals.
Figures 1 and 2 show log-normal probabil-
ity plots (Hattis and Burmaster 1994) of the
statistical uncertainty distributions for the life
stage/adult sensitivity ratios for the male and
female combined discrete and continuous dos-
ing data for mutagenic carcinogens. In this
type of plot, correspondence of the points to
the ﬁtted line is an indicator of the ﬁt of a log-
normal distribution to the statistical uncer-
tainties in central estimate life stage/adult
sensitivity ratios. (The Z-score that makes up
the x-axis is the number of SEs above or below
the median of the normal distribution of
log10-transformed values). Figures 1 and 2
show that the uncertainty distributions from
the overall ﬁts to the data are well described by
ﬁtted log-normal distributions. We stress that
these plots are of confidence limits on the
aggregate geometric mean results for all chem-
icals in the covered groups.
Departures from
Life-Stage–Speciﬁc Model Fits
from the Central Estimates for
Individual Chemicals
A risk assessor or risk manager considering
the risks of exposure to a particular carcino-
gen faces more uncertainty than the simple
statistical confidence limits on the aggregate
ﬁt of all the data quantiﬁed in the preceding
section. There is also the chance that the par-
ticular chemical under study differs in its rela-
tive life-stage–specific/adult sensitivity ratios
from the geometric mean of other chemicals
in the group providing observational data.
To give assessors and managers a prelimi-
nary set of estimates of chemical-to-chemical
differences, Table 2 shows an analysis of the
subset of the life-stage–speciﬁc carcinogenesis
data where groups of animals received expo-
sure that was confined to a single life stage
(i.e., fetal, birth to weaning, or weaning to
60-day periods). Other data points contribut-
ing to the fits in Table 1 had exposures that
extended across various life stages, were for
adults only, or were unexposed controls. At
the bottom of the table are standard devia-
tions of the common logarithms (using a base
of 10) of the departures of the chemical-
specific observations from the overall model
predictions. In the later Monte Carlo simula-
tions, the antilog of this factor will be used as
the geometric standard deviation of a log-
normally distributed multiplier for the life-
stage–specific risks with a geometric mean
of 1. Figures 3 and 4 show that, although the
data are sparse, log-normal distributions are
generally reasonable descriptions of these
data.
The limited data for the fetal life stage also
suggest greater chemical-to-chemical dif-
ferences than are present for the birth to wean-
ing and weaning to 60-day exposure periods
(Table 2). Observations in the previous report
indicated that there were substantial differences
between direct-acting chemicals (nitrosoureas)
and chemicals requiring metabolic activation
in the extent of elevation of fetal-stage carcino-
genesis sensitivity over the sensitivity to expo-
sures during adulthood.
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Table 1. Comparative results for male versus female animals for mutagenic chemicals: analysis of com-
bined data from continuous and discrete dosing experiments (nine compounds, 153 tumor incidence
observations).
Maximum likelihood estimate of cancer
inductions per dose/(body weight3/4-day) 5–95% Arithmetic
Period relative to comparably dosed adults conﬁdence limits mean
Male animals
Fetal 25 15.6–42 27
Birth to weaning 57 38–90 59
Weaning to 60 days 5.0 3.1–8.6 5.3
Female animals
Fetal 1.77 1.05–2.9 1.83
Birth to weaning 4.4 3.3–6.0 4.5
Weaning to 60 days 0.82 0.50–1.29 0.85
Data from Hattis et al. (2004).
Figure 1. Females: log-normal plots of likelihood-
based uncertainty distributions in rates of cancer
transformations per daily dose for various life stages
for mutagenic chemicals (relative to comparable
exposures of adults) for combined discrete and con-
tinuous dosing experiments. BW, body weight.
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Figure 2. Males: log-normal plots of likelihood-based
uncertainty distributions in rates of cancer transfor-
mations per daily dose for various life stages for
mutagenic chemicals (relative to comparable expo-
sures of adults) for combined discrete and continu-
ous dosing experiments. BW, body weight.
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confidence limitsThe approach represented here is not the
only possible way in which chemical-to-
chemical differences might have been ana-
lyzed. In some ways a better approach might
have been to estimate all of the coefficients
and uncertainties shown in Table 1 separately
for each chemical and sex. Had that been pos-
sible, we could have preserved for the Monte
Carlo simulations whatever dependencies
there might have been in the data between
life-stage–speciﬁc risk increments for individ-
ual chemicals. Unfortunately, this would have
required estimates of ﬁve different parameters
per sex per chemical per tumor site (the back-
ground rate of tumors, the tumor risk for
adult-only exposure, and the relative multi-
plicative increment of tumor risk for each of
the three life stages). After attempting this for
a few chemicals, we concluded that few if any
of the chemicals and tumor sites for which we
had information had rich enough data sets to
support robust estimation of the required ﬁve
independent parameters.
As an alternative, to check for dependen-
cies we did simple pairwise correlation analyses
of the data in Table 2 for different life stages.
Of the six possible pairwise correlations, we
found only one that was marginally statistically
signiﬁcant at p < 0.05—a ﬁnding that could
easily be the result of chance ﬂuctuations and
multiple comparisons. We therefore elected
not to incorporate this possible dependency
into our Monte Carlo simulation analysis of
uncertainties in overall life stage–speciﬁc risks.
Mapping Rodent Life Stages 
to Human Periods:
Implications for Uncertainties
in Projections of Expected
Risks for Lifetime Exposures 
to Mutagenic Carcinogens
A U.S. EPA committee (Brennan et al. 2003)
previously defined a series of human age
groups based on behavioral and physiologic
milestones likely to predict changes in expo-
sure rates (Table 3). Unfortunately, it is not
clear how these proposed divisions relate to
the fetal, birth to weaning, and weaning to
60-day periods used in our previous analysis
of excess risks from rodent early-life exposures
to mutagenic carcinogens. Ideally, a theory
for interspecies mapping of differences in the
timing of enhanced susceptibility for carcino-
genesis should be based on an understanding
of the carcinogenic process, and how it is
affected by age.
Considerable past work has emphasized
the potential for age-related differences in
long-term risks from carcinogenic exposures
that could result from early- versus late-life
exposure to carcinogens that tend to cause
mutations at a single stage that is either early
or late in the multistage molecular pathologic
sequence of genetic changes (Brown and Hoel
1986; Day and Brown 1980; Whittemore
1977). In general, carcinogenic risks will tend
to be greater for early-life exposure to a car-
cinogen that causes relevant early-stage transi-
tions but will tend to be greater for late-life
exposure to a carcinogen that causes relevant
late-stage transitions. For example, Figure 5
shows the effects of age at exposure on
absolute excess risks against a 10% lifetime
background cancer for classical five-stage
Armitage-Doll models in which different stage
transitions are enhanced by a carcinogenic
exposure.
Recent analyses of atomic bomb survivor
data have tended to de-emphasize this type of
mechanistic consideration. Analyses by Pierce
and Mendelsohn (1999) suggest that those
data are most compatible with a model in
which radiation enhances all stages of classical
Armitage-Doll processes (model III in Figure 5).
If this is correct, although excess relative risks
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Table 2. Log(geometric mean) departures of age-related changes in susceptibility to carcinogenesis for
individual mutagenic carcinogens from model “predictions”—combining all available cancer sites for
each agent.a
Log (observed/model predicted)
cancer transformations/animal relative to adults
Chemical Fetal Birth to weaning Weaning to 60 days
Male animals
Benzidine 0.004 0.163 –0.367
Benzo[a]pyrene ND 0.017 –0.045
Deithylnitrosamine –0.961 –0.045 0.132
DMBA ND –0.108 –0.166
Ethylnitrosourea 0.103 –0.135 0.423
N-Nitroso-N-methylurea ND –0.257 0.142
Safrole –0.486 0.084 –0.236
Urethane ND 0.008 –0.023
SD 0.490 0.132 0.249
Female animals
Benzidine –0.104 –0.111 ND
Benzo[a]pyrene ND 0.037 0.098
Diethylnitrosamine –1.086 –0.025 –0.172
DMBA ND –0.087 –0.038
Ethylnitrosourea 0.416 0.006 –0.142
N-Nitroso-N-methylurea ND –0.184 0.038
Safrole ND –0.720 ND
SD 0.763 0.269 0.115
Abbreviations: DMBA, dimethylbenz[a]anthracene; ND, no data.
aData for only eight chemicals are shown, rather than the nine listed in Table 1, because for one chemical (vinyl chloride)
there were no experimental groups where dosing was conﬁned entirely to one of the three pre-adult periods represented
here. Data combining exposures across periods and adulthood could contribute to the analysis for Table 1 because of the
use of the dummy-variable analysis methodology described in Hattis et al. (2004).
Figure 3. Males: probability plots of the individual
chemical geometric mean ratios of observed/geo-
metric mean model predicted excess cancer trans-
formations over control tumor rate/(dose/kg body
weight3/4) for treatment in various life stages relative
to adults.
Figure 4. Females: probability plots of the individual
chemical geometric mean ratios of observed/geo-
metric mean model predicted excess cancer trans-
formations over control tumor rate/(dose/kg body
weight3/4) for treatment in various life stages relative
to adults.
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ﬁrst decades after exposure, eventual lifetime
absolute risks per dose (the types of estimates
made by the U.S. EPA (1999) in its typical
slope factor assessments) are expected to be
much less influenced by age at exposure.
The most recent empirical excess absolute
risk descriptions from the atomic bomb sur-
vivor data (Preston et al. 2003) appear to
project lifetime absolute risks that are only
about twice as large for exposure before
15 years of age than for exposure between
15 and 60 years of age. It is not clear, how-
ever, that these data have been analyzed for
very fine breakdowns of early-life human
exposures (i.e., ﬁner than 10-year age periods,
such as 0–9 years); 90% of the people in
the atomic bomb survivor group who were
exposed as 0- to 9-year-olds are still alive, so it
is likely that much more extensive examina-
tion of the eventual cancer mortality experi-
ence of the youngest exposed people will be
possible in the next few decades.
One plausible factor that may be con-
tributing to life-stage–specific differences in
risks of carcinogenic transformation per unit
dose is a difference in cell replication rates for
relevant stem cells. During early life stages,
it is likely that these cells reproduce more
quickly to support the generation of additional
cells at all stages of differentiation that are
required to make up the growing organism.
Because of more rapid reproduction of such
stem cells, there is likely to be less time to
accomplish DNA repair before copying and
the ﬁxation of newly generated DNA lesions
into permanent point mutations and larger
chromosomal changes. Therefore, it is natural
to attempt to make some estimates of equiva-
lent times in different species that are related
to some measures of growth in those species.
All measures of growth, of course, are not
equally likely to be accurate reﬂections of the
kind of stem cell replication that is likely to
lead to increases in vulnerability to carcino-
genesis. Figures 6 and 7 contrast two measures
of growth—body weight versus height—that
are available for a large representative sample
of U.S. humans [from the Third National
Health and Nutrition Examination Survey
(NHANES III); National Center for Health
Statistics 1996]. Although growth in height
for average people ceases fairly abruptly at
15 or 16 years of age (depending on sex), aver-
age weights of U.S. humans continue to
increase well into middle age. Rats apparently
show a similar pattern of continual increase
in weight well into adulthood in standard
National Toxicology Program bioassay studies
(NTP 1999). Unfortunately, we were not able
to locate measurements of linear growth in
rodents that might provide more sharply
deﬁned points of comparison for the data in
Figure 6. We were, however, able to obtain
data sets for body weight covering the post-
natal (and in some cases prenatal) develop-
mental periods (Figures 8 and 9).
Failing comparable measurements of linear
growth, we elected to anchor our weight-
related estimates of relative age to another type
of developmental milestone that occurs near
the age where “adulthood” is generally
deﬁned—sexual maturity. Table 4 gives data
from a recent report (Kilborn et al. 2002)
describing times of the onset of sexual maturity
in different species. Using these developmental
anchor points, Tables 5 and 6 show the frac-
tion of sexual maturity body weights achieved
at the borders between the various rodent
exposure periods used in the prior analysis, and
the ages at which average humans of each sex
achieve the same fractions of sexual-maturity
body weights. The human ages corresponding
to rodent weaning (assumed to be 21 postnatal
days in both mice and rats) show a large varia-
tion between projections from mouse versus rat
data, and within each rodent species between
males and females. This necessarily leads to
substantial uncertainties in alternative estimates
of the amount of human time that would cor-
respond to the birth to weaning period in par-
ticular (Table 7). The length of this interval is
critical for the analysis here because the birth to
weaning period shows the greatest increase in
relative risk per dose per day of exposure
(Table 1), and the implications for lifetime
relative risk depend directly on how large a
part of the life span is covered by the “birth
to weaning” risk elevation per unit daily
dose/body weight3/4.
It is a substantial challenge to fairly represent
this uncertainty in a Monte Carlo analysis.
Some other analysts, faced with two estimates of
an uncertain quantity, have chosen to represent
the uncertainty with uniform distributions with
limits deﬁned by the two points. Our view is
that this generally understates the associated
uncertainty because there can be no assurance
that the two available estimates happen to repre-
sent the absolute lowest and highest possible
values for the uncertain parameter. We believe
that sharp limits on uncertainty distributions
should be set only where there is good reason to
believe that values outside the limits are impos-
sible (Hattis and Burmaster 1994). For the pre-
sent case, we find it hard to believe that the
human equivalent of the total period from birth
through 60 days in rodents could be more than
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Table 3. Age groupings recommended by the U.S.
EPA for early-life exposure analyses.
Age groups < 1 yeara Age groups ≥ 1 year
Birth to < 1 month 1 to < 2 years
1 to < 3 months 2 to < 3 years
3 to < 6 months 3 to < 6 years
6 to < 12 months 6 to < 11 years
11 to < 16 years
16 to < 18 years
18 to < 21 years to
be considered on a
case-by-case basis
aFor evaluating exposure or potential dose but not internal
dose, it may be acceptable to combine some of these groups
(e.g., the ﬁrst three groups could be combined to encompass
“birth to < 6 months”). Data from Brennan et al. (2003).
Figure 5. Effects of age at exposure on risks over
background for classical Armitage-Doll five-stage
multistage models in which the carcinogen
enhances different transitions over a background
lifetime risk of 10%: I, enhancement of the first
stage only; II, enhancement of the fourth stage
only; III, equal enhancement of all stages (Pierce
and Mendelsohn 1999); IV, smoking-radon analogy
two-thirds enhancement of stage I and one-third
enhancement of stage 4.
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Figure 6. Population-weighted differences in mean
height (ht) for NHANES III subjects of different
ages (2–90 years).
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Figure 7. Population-weighted differences in
log(mean weight in kg) for NHANES III subjects of
different ages (2–90 years).
2.0
1.8
1.6
1.4
1.2
1.0
L
o
g
 
(
m
a
l
e
 
b
o
d
y
 
w
e
i
g
h
t
,
 
k
g
)
0 1 02 03 04 05 06 07 08 09 0
Age (years)
Log (male body weight, kg)
Log (female body weight, kg)about 15 years in females or 16 years in males—
corresponding to the average cessation of ver-
tical growth seen in the NHANES III data
(Figure 6). We therefore chose to deﬁne log-
normal uncertainty distributions as shown in
Table 7 for human equivalents of the various
rodent exposure periods, subject only to the lim-
itation that within any Monte Carlo trial, the
total birth to weaning plus weaning to 60-day
equivalents could not exceed these sex-depen-
dent limits. In cases where these limits were
exceeded on individual trials, both the compo-
nent periods were reduced proportionately to
values that would add up to the prescribed lim-
its. This introduced a negative dependency
between possible values for the birth to weaning
and weaning to 60-day periods.
Monte Carlo Simulation
Modeling of the Uncertainties
in Full-Life Exposures to a
Generic Mutagenic Carcinogen
Using the Microsoft Excel rand( ) and norm-
sinv( ) commands, (Microsoft Excel X for
Mac, Microsoft Corp., Redmond, WA) each
simulation trial drew random values for a
particular sex for the central estimate of the
risk/dose multiplier for each of the three peri-
ods relative to adults (see Figures 1 and 2 for
log-normal parameters), the chemical-to-
chemical relative risk multiplier [geometric
mean of 1 and log(geometric standard devia-
tions) in Table 2], and the length of the
human equivalents of the three periods,
subject to the 15- and 16-year limitations
described above.
The period-speciﬁc increments to lifetime
risk (relative to comparable adult period expo-
sure, deﬁned as 1) were then calculated as the
product of these three terms normalized to
the calculated duration of the adult period for
that trial. (The length of the adult period var-
ied from trial to trial as the difference between
70 years and the sum of the human-equiva-
lent birth to weaning and weaning to 60-day
periods.) The model spreadsheets available on
the website (Hattis 2004) should be consulted
for further methodologic details.
The uncertainty distributions for the sex-
speciﬁc and life-stage–speciﬁc contributions to
expected lifetime risk are given in Table 8.
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Figure 8. Postnatal growth of Sprague-Dawley rats,
based on data compiled for the U.S. EPA. Data from
Gentry et al. (2003). BW, body weight.
3.5
3.0
2.5
2.0
1.5
1.0
0.5
R
a
t
 
l
o
g
 
(
g
 
B
W
)
0 20 40 60 80 100
Age (days)
Male
Female
Figure 9. Postnatal growth of ICR/Jcl mice, based
on data from Nomura (1976). Abbreviations: BW,
body weight; PND, postnatal day.
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Table 4. Species differences in times of beginning
sexual maturity.
Species (time unit) Male Female
Mouse (months) 1.5 1.0
Rat (months) 1.8–2.1 1.8–2.1
Human (years) 11.5 10.5
Data from Kilborn et al. (2002).
Table 5. Mice: inferences of corresponding human ages from weight-based comparisons relative to the
times of sexual maturity.
Fraction of
mouse weight at Source of human Corresponding Unit of
Time/event sexual maturity weight data human age human age
Male mouse
Begin fetal dosing (GD12) 6.4 × 10–4 Potter and Craig 1975 93 Gestation days
Birth (GD20) 0.048 Potter and Craig 1975 35 Gestation weeks
Weaning (PND21) 0.354 NHANES III 3.16 Postnatal years
Adult (PND60) 1.163 NHANES III 12.8 Postnatal years
Female mouse
Begin fetal dosing (GD12) 1.8 × 10–3 Potter and Craig 1975 112 Gestation days
Birth (GD20) 0.092 Sunderman and Boerner 1949 14 Postnatal days
Weaning (PND21) 0.677 NHANES III 7.40 Postnatal years
Adult (PND60) 1.435 NHANES III 15.1 Postnatal years
Abbreviations: GD, gestation day; PND, postnatal day.
Table 6. Rats: inferences of corresponding human ages from weight-based comparisons relative to the
times of sexual maturity.
Fraction of
mouse weight at Source of human Corresponding Unit of
Time/event sexual maturity weight data human age human age
Male rat
Begin fetal dosing (GD12) 6.3 × 10–5 Potter and Craig 1975 66 Gestation days
Birth (GD22) 0.023 Potter and Craig 1975 28 Gestation weeks
Weaning (PND21) 0.195 NHANES III 0.44 Postnatal years
Adult (PND60) 1.035 NHANES III 11.7 Postnatal years
Female rat
Begin fetal dosing (GD12) 6.3 × 10–5 Potter and Craig 1975 66 Gestation days
Birth (GD22) 0.029 Potter and Craig 1975 30 Postnatal weeks
Weaning (PND21) 0.250 NHANES III 0.90 Postnatal years
Adult (PND60) 1.025 NHANES III 10.6 Postnatal years
Abbreviations: GD, gestation day; PND, postnatal day.
Table 7. Estimated lengths of various life stages in humans inferred from the ages of sexual maturity in
mice, rats, and humans, and patterns of growth of body weight for rodents through 60 days of age, and for
humans through 16 years of age.
Mouse-based Rat-based Geometric Geometric
Rodent sex and life-stage equivalent estimate (days) estimate (days) mean (days) SD
Males
GD12 to birth (fetal) 150 134 142 1.11
Birth to weaning 1,180 235 527 3.94
Weaning to 60 days 3,510 4,130 3,810 1.15
Females
GD12 to birth (fetal) 175 142 157 1.20
Birth to weaning 2,690 392 1,030 5.12
Weaning to 60 days 2,830 3,560 3,170 1.22
GD, gestation day.All data for this table were rounded to three signiﬁcant ﬁgures. This overstates the likely accuracy of the
underlying projections. However, three signiﬁcant ﬁgures are retained here to allow reasonably accurate reproduction of
our later calculations by other analysts.In each case the numbers represent the incre-
ment to lifetime relative risk/dose where the
risk from treatment for the full adult period is
deﬁned as 1. For example, the 50th percentile
of the uncertainty distribution under the “male
fetal” column is 0.173. This means that treat-
ment at the similar dose rate to the mother
through the fetal period (rodent gestation day
12 equivalent through birth) is expected to
produce about 17% of the lifetime risk of
exposure to the generic mutagenic carcinogen
through the entire period of adulthood.
The potential aggregate public health sig-
nificance of these results can be seen in the
“bottom line” distributions provided in Table 9.
The ﬁnal column, aggregating results for males
and females, suggests that full lifetime risks for
full life constant exposure per kilogram of body
weight3/4 to a generic mutagenic carcinogen
are expected to be about 3.5 times larger than
would be estimated for similar exposure only
through the full period of adulthood. There is
appreciable uncertainty in this estimate (with
5–95% conﬁdence limits corresponding to a
range from a 60% increment to nearly an
8-fold increment from adult-only exposure),
but it gives analysts and decision makers a start-
ing point for reasoning about the potential risks
from early-life exposures to particular agents.
The milligram per kilogram body weight3/4
scenario quantiﬁed in Table 9 represents a rea-
sonable generic case for exposure via an envi-
ronmental medium (e.g., air) whose intake
depends on metabolism rates, which scale
approximately with the three-quarters power of
body weight. However, because many current
risk assessments are done based on dosages
expressed in milligrams per kilogram, rather
than milligrams per kilogram body weight3/4,
Table 10 and Figure 10 show comparable
results for a scenario in which there is constant
lifetime exposure in terms of simple milligrams
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Table 8. Detailed results by life stage and sex: uncertainty distributions of risks for full lifetime exposures
to a generic mutagenic carcinogen at a constant dose rate per kilogram body weight3/4.
Risk relative to adult period
Percentile of uncertainty distribution Fetal Birth to weaning Weaning to 60-day
Males
1 0.011 0.054 0.167
2.5 0.018 0.084 0.217
5 0.026 0.135 0.273
10 0.039 0.220 0.365
25 0.078 0.565 0.563
50 0.173 1.44 0.882
75 0.392 3.77 1.38
90 0.764 7.79 2.03
95 1.20 10.7 2.53
97.5 1.72 13.2 3.18
99 2.89 17.4 3.91
Arithmetic mean 0.351 2.92 1.09
Females
1 0.000 0.004 0.012
2.5 0.000 0.007 0.021
5 0.001 0.012 0.034
10 0.001 0.023 0.049
25 0.004 0.069 0.074
50 0.014 0.210 0.107
75 0.047 0.564 0.150
90 0.137 1.09 0.199
95 0.278 1.57 0.233
97.5 0.505 2.10 0.273
99 0.961 2.79 0.323
Arithmetic mean 0.072 0.432 0.118
The numbers represent the increment to lifetime relative risk/dose where the risk from treatment for the full adult period
is deﬁned as 1.
Table 9. Overall results for constant mg/kg body weight3/4 dosing: uncertainty distributions of full lifetime
risks for lifetime exposures to a generic mutagenic carcinogen at a constant dose rate per kilogram body
weight3/4.
Full lifetime risk relative to adult period only
Percentile of uncertainty distribution Male Female Male and female population
1 1.71 1.19 1.45
2.5 1.87 1.20 1.53
5 2.04 1.22 1.63
10 2.28 1.25 1.76
25 2.91 1.31 2.11
50 4.10 1.46 2.78
75 6.51 1.78 4.15
90 10.2 2.33 6.26
95 13.0 2.77 7.89
97.5 15.9 3.33 9.62
99 19.5 4.06 11.8
Arithmetic mean 5.38 1.66 3.52
Table 10. Overall results for constant mg/kg body weight1 exposures: uncertainty distributions of full life-
time incremental risks for lifetime exposures to a generic mutagenic carcinogen at a constant dose rate
per kilogram body weight1.
Full lifetime risk relative to adult period only
Percentile of uncertainty distribution Male Female Male and female population
1 1.53 1.15 1.34
2.5 1.65 1.16 1.41
5 1.76 1.18 1.47
10 1.92 1.19 1.56
25 2.34 1.24 1.79
50 3.19 1.34 2.27
75 4.85 1.58 3.22
90 7.54 1.98 4.76
95 9.69 2.34 6.02
97.5 11.7 2.72 7.19
99 14.5 3.43 8.98
Arithmetic mean 4.10 1.50 2.80
Figure 10. Summary of mean model predictions for
the lifetime risk increment/(mg/kg dose-day) from
constant mg/kg-day exposures of children of various
ages (squares) compared with the U.S. EPA’s pro-
posed assumptions (U.S. EPA 2003). Est, estimated.
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Est risk/(mg/kg dose) relative adult
U.S. EPA proposed risk/dose relative adult
U.S. EPA proposed risk assessment assumptions
Defined adult lifetime risk per daily mg/kg doseper kilogram body weight1. This scenario also
allows a direct comparison with expectations
under the U.S. EPA proposal (EPA 2003) of
factors of 10 and 3 for relative susceptibility
per milligrams per kilogram dose for the ﬁrst
2 years, and ages 2–15, respectively. Overall,
Monte Carlo simulations using the constant
milligrams per kilogram dosing produce a mean
expected value for the lifetime risk that is
2.8 times what would be expected for adult-
only exposure (compared with the 1.6 expected
under the U.S. EPA proposal; U.S. EPA 2003)
with 5–95% confidence limits of about
1.5–6 times the adult-only exposure risk. For
the U.S. EPA’s 0- to 2-year and 2- to 15-year
age groups (EPA 2003), we ﬁnd mean expected
risk increments of 13.7- and 4.7-fold relative
to mean adult exposure risks, respectively.
These are in the range of 35–55% larger than
expected using the U.S. EPA’s proposed 
10- and 3-fold factors (EPA 2003). Overall,
these are not large differences, considering the
relatively informal nature of the analysis under-
lying the U.S. EPA proposal; however, these
results suggest that further studies may well
suggest somewhat larger adjustments.
Both Tables 9 and 10 give results for each
sex separately for completeness. However, to
the degree that the sex-dependent differences
in age-related susceptibility depend on sexual
dimorphisms in CYP enzyme expression,
readers should be cautioned that some CYP
enzymes known to be expressed in a sex-
related fashion in rats do not appear to corre-
spond to CYP enzymes that are known to be
present in humans (Mugford and Kedderis
1998). In the absence of direct human evi-
dence that there are sex-related differences in
age-specific susceptibility as substantial as
those indicated in Tables 9 and 10, we rec-
ommend that risk assessors give most empha-
sis to the total population projections (both
sexes combined) in evaluating the potential
signiﬁcance of early-life exposures.
There is one other “bottom line” infer-
ence that should be made clear. The results in
Tables 9 and 10 directly imply that it is more
likely than not that most of the total lifetime
risk of cancers from continuous milligrams
per kilogram-day or milligrams per kilo-
gram3/4-day exposures to mutagenic carcino-
gens arises from exposures that are received
before adulthood.
Brief Discussion of Further
Needs for Risk and Uncertainty
Modeling to Estimate Full Life
Mutagenic Cancer Risks for a
Generic Example Chemical
Full application of these results to a real exam-
ple chemical would ideally involve several
additional steps: a) quantiﬁcation of any dif-
ferential exposure of children of various life
stages relative to adults; b) integration of infor-
mation from all available animal bioassays
deemed acceptable for human risk projections;
c) adjustments, if needed, for the inclusion of
a portion of the “weaning to 60-day” period in
the bioassays for the chemical, if the bioassays
began exposures before our assumed 60-day
starting point; d) integration of likelihood-
based uncertainties in estimated dose–response
slopes from the bioassay data into the overall
uncertainty analysis; and e) incorporation of
estimates of delivered dose, across species and
life stages, preferably with the aid of physio-
logically based pharmacokinetic models, along
with pharmacodynamic uncertainties in inter-
species projections.
For example, data for induction of breast
cancers by dimethylbenz[a]anthracene clearly
indicate greater sensitivity in adolescent ani-
mals than either earlier or later in life (56%
tumor incidence in 6–8 week animals, com-
pared with 8% for females < 2 weeks of age
and 15% for 26-week animals) (Ginsberg
2003; Meranze et al. 1969). [These specific
data were not separately broken out by the
U.S. EPA (2003) in its primary listing of
data, and thus were included only in the form
of a “total tumors” category in our original
analysis (Hattis et al. 2004).] The observed
age-dependent pattern of tumor induction
in the breast is probably related to the cell
division pattern in terminal end buds in the
development of that tissue (Russo and Russo
1999). Human data for this parameter (Russo
et al. 1987) might allow a greatly improved
rodent-to-human equivalent age mapping for
this tumor type.
Conclusions
Improved life-stage–speciﬁc analyses are pos-
sible based on current information. These
involve appreciable uncertainties, particularly
in the mapping of rodent exposure periods to
human equivalents. However, current under-
standing can at least provide decision makers
and the public with preliminary estimates of
the potential importance of exposures at early
life stages in the overall context of cancer risks
from genetically active agents. The suggestion
of the present analysis is that early-life expo-
sure could make important contributions to
full-life cancer risks.
However, we offer the caveat that, because
of the multistage and multifactor nature of
cancer development, these analyses should be
grounded on the mode of action of the spe-
ciﬁc agent or classes of agents with putatively
similar modes of action. Speciﬁc agents affect-
ing tumors at particular sites may also have
different age patterns of sensitivity than the
general run of mutagenic carcinogens repre-
sented in the present analysis. The present
results are based on early-life sensitivity data
for only nine chemicals, of which only five
were classiﬁed as mutagenic. The conclusions
about early-life sensitivity for carcinogens with
different sites or modes of action could be
altered as data become available for bioassays
testing age-related differences in tumor risks
after exposures to a broader set of chemicals.
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